Sensei Biotherapeutics (FTH) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Sensei Biotherapeutics (NASDAQ: FTH):

• 7/31/2026 – Sensei Biotherapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $56.00 price target on the stock.
• 7/28/2026 – Sensei Biotherapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $60.00 price target on the stock.
• 7/20/2026 – Sensei Biotherapeutics is now covered by Citizens Jmp. They set an “outperform” rating and a $51.00 price target on the stock.
• 7/16/2026 – Sensei Biotherapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $55.00 price target on the stock.
• 6/26/2026 – Sensei Biotherapeutics is now covered by Robert W. Baird. They set an “outperform” rating and a $57.00 price target on the stock.
• 6/25/2026 – Sensei Biotherapeutics was upgraded by Robert W. Baird to “strong-buy”.
• 6/22/2026 – Sensei Biotherapeutics is now covered by HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
• 6/17/2026 – Sensei Biotherapeutics is now covered by Weiss Ratings. They set a “sell (d-)” rating on the stock.
• 6/11/2026 – Sensei Biotherapeutics was upgraded by BTIG Research to “strong-buy”.
• 6/11/2026 – Sensei Biotherapeutics is now covered by BTIG Research. They set a “buy” rating and a $55.00 price target on the stock.
• 6/4/2026 – Sensei Biotherapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.

Insider Transactions at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson bought 9,391 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the transaction, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 49,494 shares of company stock valued at $1,188,822 in the last three months. 7.00% of the stock is currently owned by company insiders.

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.